WuXi AppTec is excited to exhibit at this year’s 42nd Annual Meeting of the American College of Toxicology (ACT). The event runs from November 14-17, 2021, and will be held at Gaylord National Harbor located just outside Washington D.C.
The ACT Annual Meeting brings together professional scientists from the pharmaceutical and biotech industries, regulatory agencies, laboratory testing partners, academia and consulting firms. This year’s meeting promises a robust scientific program including continuing education courses, scientific sessions, distinguished plenary speakers, a poster viewing session (Nov. 15) and several social events to facilitate professional networking. Some activities will require prior registration or invitation to attend.
WuXi AppTec Participation in ACT
WuXi AppTec’s presence at this year’s ACT annual meeting, senior technical director, Dr. Mark Walker, is scheduled to host an exhibitor session titled “Trends for Resource Use in Drug Development: Origins, Supplies, Alternatives and the 3Rs.”
Dr. Walker has more than 25 years of preclinical toxicology experience and is an expert in Investigational New Drug (IND) applications, primate toxicology and regulatory interactions. Learn more from him during his presentation and have the ability to ask your most pressing toxicology questions.
During this year’s ACT session, Dr. Walker will take you through the latest trends, how resource shortages are impacting development and what you can do to mitigate delays. The presentation will also cover:
- The differences in strains and origins and how to best optimize them
- Age and sexual maturity requirements for best results
- Possible resource alternatives to keep your program on track.
Dr. Walker will also continue the important dialogue around replacement, reduction and refinement in drug development.
WuXi AppTec is also a Gold Supporter of this year’s annual meeting and as such, is scheduled to exhibit in booth #114. Interested parties are encouraged to stop by the booth and schedule time to meet with one of WuXi AppTec’s drug development subject matter experts. The full list of exhibitors is veritable who’s who of pharmaceutical and biotech organizations.
What You Need to Know
In an effort to keep the event as safe as possible, ACT will implement preventative measures to reduce the spread of COVID-19 for all participants. Registrants will be asked to sign an Assumption of Risk and Release Wavier prior to entry. ACT will also ask attendees to practice social distancing and wear face coverings at all times. ACT will adjust this policy if federal guidelines change before the event starts.
International travelers are encouraged to apply early for U.S. entry visas as they can take up to four months to process.
For more information or to register, please visit: ACT Registration
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling around 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”
